Facebook
Twitter
LinkedIn
ForwardPersonalization of Systemic Therapy for Localized to Metastatic Prostate Cancer (PRO 10)
This session has three speakers who walk through the use of systemic therapy across the spectrum of prostate cancer. First, we cover emerging evidence and tools on how to select patients for ADT in intermediate risk and post op patients. The next speaker covers personalizing systemic therapy in patients with localized high risk and node positive prostate cancer. The final speaker covers the landscape of systemic therapies for prostate cancer and discuss where radiation to the primary, metastasis directed therapies for oligometastatic disease, and Pluvicto fit in with other systemic therapies.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation oncology residents, and urologists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Determine what data and testing is available to tailor the use of ADT in intermediate risk and post prostatectomy patients.
- Explain the combinations and sequencing of systemic therapies for high risk, node positive, and metastatic prostate cancer patients.
Thomas P. Boike, MD, FASTRO, MMM, is employed by GenesisCare USA/Michigan Healthcare Professionals. Dr. Boike receives honoraria from ASTRO APEx and Blue Earth Diagnostics. He receives compensation from Boston Scientific, Lantheus, and Palette Life Sciences. He previously received honoraria from Medivation/Astellas, Janssen, Elekta, AstraZeneca, Myovant, and Pfizer. He serves as Co-chair of the ASTRO APEx committee, he is a Member of the NCI Prostate Cancer Task Force, and a Board Member of the Michigan Institute of Urology Foundation.
Angela Y. Jia, MD, PhD, is employed by University Hospitals Seidman Cancer Center, Case Western Reserve University. Dr. Jia previously received honoraria from Myovant.
Anne Wagner Rajkumar, MD, is employed by Mayo Clinic. She was previously employed by Vanderbilt University Medical Center. She served as a panel participant during the 2023 ASTRO Annual Meeting.
Rana R. Mckay, MD, is employed by the University of California, San Diego. Dr. Mckay receives compensation from Janssen, Novartis, Tempus, Exelixis, Pfizer, BMS, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix and Eli Lilly. Dr. Mckay serves as an Editorial Board Member of the Journal of Clinical Oncology.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.